Physician profile
Rollie D Rosete
NPI 1801838610
$8,418.38
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $2,038 · 2021: $1,847 · 2022: $1,372 · 2023: $1,167 · 2024: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,390.08 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Kowa Pharmaceuticals America, INC. | $782.14 | 2019-2023 | Seglentis, Livalo |
| Abbvie INC. | $729.99 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $702.93 | 2019-2022 | |
| Lilly USA, LLC | $587.58 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $408.42 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $358.17 | 2019-2023 | |
| Allergan, INC. | $346.64 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $342.26 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $310.84 | 2022 | |
| Merck Sharp & Dohme LLC | $291.99 | 2019-2023 | Belsomra |
| Scilex Pharmaceuticals INC. | $244.64 | 2019-2022 | |
| Astellas Pharma US INC | $194.90 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $171.89 | 2019-2023 | Xarelto |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $160.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $137.91 | 2019-2020 | |
| Amgen INC. | $123.08 | 2020-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $88.47 | 2019-2022 | |
| Eisai INC. | $70.49 | 2021 | |
| Amag Pharmaceuticals, INC. | $64.65 | 2019 | |
| Idorsia Pharmaceuticals US INC | $55.89 | 2023-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $54.92 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.98 | 2021-2022 | |
| Lundbeck LLC | $41.11 | 2022-2023 | Rexulti |
| Qiagen, LLC | $33.11 | 2020-2022 | |
| Nevro Corp. | $24.22 | 2023 | Senza |
| Amarin Pharma, INC. | $22.53 | 2019 | |
| Hologic Sales and Service, LLC | $21.07 | 2019 | |
| Optos, INC. | $20.58 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.45 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $19.41 | 2022 | |
| Genentech USA, INC. | $19.37 | 2022 | |
| Emergent Biosolutions INC. | $15.07 | 2019 | |
| Ibsa Pharma INC. | $14.54 | 2023 | Tirosint, Licart |
| Sumitomo Pharma America, INC. | $11.48 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rollie Rosete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.